Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00183742
Status:
COMPLETED
Last Update Posted:
2014-05-22
First Post:
2005-09-09
Brief Title:
Trial of Liposomal Doxorubicin Doxil and Weekly Docetaxel Taxotere
Sponsor:
University of Southern California
Organization:
University of Southern California
Study Overview
Official Title:
Phase I Trial of Liposomal Doxorubicin Doxil and Weekly Docetaxel Taxotere
Status:
COMPLETED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is for patients with advanced cancer that has failed treatment with conventional therapy or for which no standard treatment exists The purpose of this study is to determine the highest dose that can be given of 2 chemotherapy drugs docetaxel also called Taxotere and liposomal doxorubicin also called Doxil when given together and to determine the side effects of this combination Both Taxotere and Doxil are chemotherapy drugs that can decrease the size of several different tumors Taxotere is approved by the Food and Drug Administration FDA for the treatment of breast and lung cancers and Doxil is approved for the treatment of ovarian cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None